# A Study of SEA-CD40 Given With Other Drugs in Cancers

> **NCT04993677** · PHASE2 · COMPLETED · sponsor: **Seagen Inc.** · enrollment: 77 (actual)

## Conditions studied

- Melanoma
- Carcinoma, Non-Small- Cell Lung

## Interventions

- **DRUG:** SEA-CD40
- **DRUG:** pembrolizumab (KEYTRUDA®)
- **DRUG:** pemetrexed
- **DRUG:** carboplatin

## Key facts

- **NCT ID:** NCT04993677
- **Lead sponsor:** Seagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-10-06
- **Primary completion:** 2024-01-03
- **Final completion:** 2024-11-25
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2025-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04993677

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04993677, "A Study of SEA-CD40 Given With Other Drugs in Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04993677. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*